Prof. Dr. med. Marc O. Schurr

Managing Director
info@novineon.com
+49-(0)7071 / 98 979-130

has substantial professional experience in the global healthcare industry. This concerns not only Research & Development, but also the market side. He attended medical school in Tuebingen, Germany, including stays in the US and Italy, and took his doctoral degree following relevant research in the area of medical technologies. After graduation from medical school he attended business education at the St. Galler Management Seminar.  Prior to foundation of novineon Prof. Schurr has been working in medical research and management consulting. Prof. Dr. med. Marc O. Schurr has been conducting clinical evaluations since 2003. He has been clinical trial investigator since 2007.

Dr. rer. nat. Marion Fehlker

Director of Operations, authorized representative
marion.fehlker@novineon.com
+49-(0)7071 / 98 979-124

studied chemistry with biochemistry as a major subject at the University of Stuttgart. Subsequently, she did a doctorate in biology with the main focus on biochemistry/molecular biology at the Charité in Berlin. From 2005 – 2009 she worked as a post-doc in biomedical research at the Max-Delbrück-Centrum in Berlin, mainly studying the molecular biology of colorectal carcinoma. Since July 2010, Dr. Marion Fehlker is responsible for clinical evaluations at novineon CRO GmbH. Since 2013, she is certified “Manager Regulatory Affairs Medical Devices International”. Dr, Marion Fehlker has been trained by CenTrial (Tuebingen) in the planning of clinical trials. Since 2016, she is “Director of Operations” of the service division of novineon CRO GmbH.

Dr. rer. nat. Timo Weiland

Director Research & Development, authorized representative
timo.weiland@novineon.com
+49-(0)7071 / 98 979-123

studied biology at the University of Konstanz and gained his doctoral degree at the Department of Biochemical Pharmacology in 2007. There, he continued conducting research in the field of hepatic cell death and cytoprotective signalling pathways until 2008. Afterwards, he continued his work at the University Hospital Tuebingen within the Collaborative Research Centre SFB 773 “Therapy Resistance of Solid Tumours”.

In September 2011, Dr. Weiland joined novineon CRO GmbH, where he is responsible for clinical evaluations. In 2013, he successfully completed the Certificate Course “Medical Device Regulatory Affairs” at the Centre for Further Education and Transfer of Knowledge (ZWW) at the University of Augsburg. Dr. rer. nat. Timo Weiland is certified as clinical data manager.

Dr. rer. nat. Marc Brändle

Consultant
marc.braendle@novineon.com
+49-(0)7071 / 98 979-136

did his Bachelor’s and Master’s degree in molecular medicine at the University of Tuebingen. From 2011 to 2012, within the course of the 4-year BACHELOR PLUS studies with integrated flexibility window, he was enrolled in human medicine at the Medical University of Innsbruck. From 2014 to 2018, he did his doctoral studies in biochemistry at the Interfaculty Institute of Biochemistry (IFIB) in Tuebingen with focus on the molecular biology of Non-Hodgkin Lymphoma. Since July 2018, Dr. Marc Brändle has been responsible for clinical evaluations of medical devices at novineon CRO GmbH.

Timo Brueggemann, Msc.

Consultant
timo.brueggemann@novineon.com
+49-(0)7071 / 98 979-140

studied neurobiology with the additional major of ethics in the life sciences at the Eberhard Karls University of Tuebingen. For his master thesis at the Werner Reichardt Centre for Integrative Neuroscience (CIN), section Systems Neurobiology at the University of Tuebingen, Timo Brueggemann researched the effects of an anesthetic agent (Tricaine/MS-222) and gradual cooling on the neuronal activity in the hindbrain and optical tectum of transgenic zebrafish via optogenetics. Since November 2021, Timo Brueggemann has been responsible mainly for clinical evaluations at novineon CRO GmbH.

Dr. rer. nat. Benedikt Fabry

Consultant
benedikt.fabry@novineon.com
+49-(0)7071 / 98 979-127

studied Biology with a focus on plant physiology, virology and pharmacology at the University of Hohenheim. He conducted his Diploma at the Institute of Plant Physiology and Biotechnology at the University of Hohenheim. During his PhD project he studied the influence of the protein Torsin1A on the development of the central nervous system at the Institute of Medical Genetics and Applied Genomics of the Eberhard Karls University Tübingen, where he worked on further scientific projects after his graduation. Dr. rer. nat. Benedikt Fabry has been trained by CenTrial (Tuebingen) in the planning and conducting of clinical trials. Since February 2018, he is responsible for clinical evaluations at novineon CRO GmbH.

Maren Foehlisch

Project and team assistant
maren.foehlisch@novineon.com
+49-(0)7071 / 98 979-132

Dragana Galevska, Msc.

Consultant
dragana.galevska@novineon.com
+49-(0)7071 / 98 979-126

studied Biomedical Technologies at the Eberhard Karls University of Tuebingen. She worked as a researcher at the Hertie Institute for Clinical Brain Research on concurrent closed-loop EEG–TMS (electroencephalography-transcranial magnetic stimulation), as well as on rTMS- (repetitive transcranial magnetic stimulation) clinical trials for stroke patients. For her master thesis at the neurological and neuroradiological department of the University Hospital Tübingen, Dragana Galevska investigated morphological and functional biomarkers by means of DTI-MRI (Diffusion Tensor Imaging – Magnetic Resonance Imaging) to predict response to therapeutic brain stimulation in chronic stroke patients. Since May 2021, she has been part of the novineon CRO team and is primarily concerned with clinical evaluations and FDA submissions Biomedical Technologies an der Eberhard-Karls-Universität Tuebingen.

Amko Groeneveld, B.Sc.

Consultant
amko.groeneveld@novineon.com
+49-(0)7071 / 98 979-147

studied medical technologies in a cooperative study program of the Universität Stuttgart and the Eberhard-Karls-Universität Tübingen, all the while gathering extensive knowledge of both the human physiology and engineering disciplines. For his Bachelor thesis, he evaluated the influence of prolonged standing and walking periods on the volume of the participant’s calf at the Institut für Arbeitsmedizin, Sozialmedizin und Versorgungsforschung in Tübingen. Since October 2018, Mr. Groeneveld initially supported the operational processes of novineon CRO GmbH, and since January 2021, he has been working in the area of clinical evaluations.

R. Haupt, M.Sc.

Consultant
rebecca.haupt@novineon.com
+49-(0)7071 / 98 979-135

Dominik Heiss, BSc.

Consultant
dominik.heiss@novineon.com
+49-(0)7071 / 98 979-150

studied medical technology from 2017 – 2021 at the University of Furtwangen and acquired comprehensive knowledge in human physiology as well as engineering disciplines. From September 2019 to March 2020, Mr. Heiss gained practical experience in quality management and regulatory affairs at a medical technology start-up in the field of cardiopulmonary support. As part of his bachelor thesis at a company active in regulatory affairs and quality management, Mr. Heiss created a concept and a prototype for a learning management system. In October 2021, Mr. Heiss joined novineon CRO GmbH, where he is responsible for clinical evaluations.

Dr. rer. nat. Maria Kiel

Consultant
maria.kiel@novineon.com
+49-(0)7071 / 98 979-134

studied biology with a focus on neurobiology at the Eberhard Karls University Tübingen. She proceeded to her doctorate at the Graduate Training Center of Neuroscience, International Max Planck Research School at the Eberhard Karls University of Tübingen. During her PhD research, Dr. Maria Kiel investigated the representation of abstract quantities and decisions by individual cells in the prefrontal cortex. After completing her PhD thesis, Dr. Maria Kiel worked in medical publishing. Her working activities included research, medical writing and project management. Afterwards Dr. Maria Kiel worked in technical marketing for measurement technology. In June 2020 Dr. Maria Kiel joined novineon CRO GmbH, where she is responsible for clinical evaluations.

Dr. rer. nat. Natalja Klymov

Consultant
natalja.klymov@novineon.com
+49-(0)7071 / 98 979-150

studied biology with specialization in neurobiology at the Eberhard-Karls-University of Tübingen. Thereafter, she did her doctoral studies in neuroscience at the Graduate Training Center of Neuroscience, International Max Planck Research School at the University of Tübingen. During her PhD research, she investigated the neuronal mechanisms underlying cognitive control of vocal production. In the course of her doctorate, her tasks included data collection using electrophysiology and c-fos immunocytochemistry, literature research and scientific writing. Since April 2021 she has been responsible for clinical evaluations of medical devices at novineon CRO GmbH.

Elke Krapp, Dipl.-Ing. (BA)

Consultant
elke.krapp@novineon.com
+49-(0)7071 / 98 979-122

Sebastian Lorscheid, M.Sc.

Consultant
sebastian.lorscheid@novineon.com
+49-(0)7071 / 98 979-137

studied molecular biology with special focus on medical biology and biochemistry at the Westfälische Hochschule. For his master thesis he moved to the Interfaculty Institut of Biochemistry (IFIB) in Tuebingen, where he analyzed the regulation of murine macrophage functionality during inflammation. Sebastian Lorscheid continued his work at the IFIB to receive a PhD degree in biochemistry, which he will complete in 2020. Topic of this thesis are the progression and regulation of psoriasis in different mouse models. Since May 2020, Sebastian Lorscheid has been responsible for clinical evaluations at novineon CRO GmbH.

Dr. rer. nat Anna Manawapat-Klopfer

Consultant
anna.manawapat-klopfer@novineon.com
+49-(0)7071 / 98 979-131

studied Biology with special subjects cell biology, parasitology and virology at the University of Tuebingen. She gained her doctoral degree in 2013 in the field of virology at the University Hospital Tuebingen. Main research topic was the identification of biomarkers for the persistence and progression of a Human Papilloma Virus Type 16 infection. From 2013 – 2015 she continued her work as a post-doc. Besides her own publication she has contributed to other publications during her PhD. Dr. rer. nat. Anna Manawapat-Klopfer has been trained by CenTrial (Tuebingen) in the planning of clinical trials. Since June 2015, Anna Manawapat-Klopfer is responsible for clinical evaluations at novineon CRO GmbH.

Dr. rer. nat. Stefanie Meese

Consultant
stefanie.meese@novineon.com
+49-(0)7071 / 98 979-129

Iweta Metzger, M.Sc.

Consultant
iweta.metzger@novineon.com
+49-(0)7071 / 98 979-128

studied Molecular Nutritional Science with special focus on experimental research, genetics and molecular mechanisms at the University of Hohenheim. For her master thesis at the Institute of Animal Science, Iweta Metzger investigated the effect of metformin on the intestinal microbial community of mice. In an experimental project at the University of Vienna she conducted research on the aging-associated modification of intestinal homeostasis and barrier function. Iweta Metzger specialized in the legal aspects of food law, pharmaceutical and medical technological regulations during her semester in Vienna. Since February 2019, she has been responsible for clinical evaluations at novineon CRO GmbH. Iweta Metzger has been trained in the planning and conducting of performance evaluations and performance studies of in vitro diagnostics.

Marie Peschka

Human resources, finance and accounting
marie.peschka@novineon.com
+49-(0)7071 / 98 979-125

Dr. rer. nat. S. Rohrer

Consultant
sabrina.rohrer@novineon.com
+49-(0)7071 / 98 979-133

C. Tschirner, Dipl. Biol.

Consultant
claudia.tschirner@novineon.com
+49-(0)7071 / 98 979-138

Dr. rer. nat. Nicole Zabel

Consultant
nicole.zabel@novineon.com
+49-(0)7071 / 98 979-149

studied biochemistry with special focus on clinical chemistry and molecular cell biology in tumor development at the Technische Universität München. For her master thesis at the Institute of Biochemistry and Technical Biochemistry at the University of Stuttgart, Nicole Zabel analyzed the degradation of artificial misfolded proteins of the endoplasmic reticulum in baker’s yeast. From 2013 – 2019, she continued her work to receive a PhD degree, which will be completed in summer 2020. Since February 2020, Nicole Zabel has been responsible for clinical evaluations at novineon CRO GmbH. Nicole Zabel has been trained in the planning and conducting of performance evaluations and performance studies of in vitro diagnostics.